Erck Stanley C 4

What Happened Stanley C. Erck, a director of MaxCyte, received equity awards on June 17, 2026 totaling 80,000 restricted stock units (RSUs). The Form 4 shows two grant line items: 30,421 RSUs and 49,579 RSUs, each recorded at $0.00 (award/grant). These RSUs are contingent rights to receive one share of MaxCyte common stock per RSU and vest on June 17, 2027 subject to continuous service.

Key Details

• Transaction date: June 17, 2026; Form 4 filed June 22, 2026 (appears to be filed after the 2-business‑day window).
• Grant details: 30,421 RSUs (non‑derivative line) + 49,579 RSUs (derivative line) = 80,000 RSUs total; acquisition price $0.00.
• Vesting: Shares underlying the grant vest on June 17, 2027, contingent on continuous service (per footnotes).
• Footnotes: F1 = RSUs represent contingent right to one share each. F2 = Annual grant under the issuer’s Equity Grant Policy for non‑employee directors.
• Shares owned after the transaction: Not specified in the provided filing excerpt.

Context RSU grants to non‑employee directors are routine compensation and do not involve an open‑market purchase or sale. Because these are contingent RSUs, no shares were issued immediately—conversion to actual shares will occur only if vesting conditions are met. Note the filing date (June 22) is several days after the transaction date; late Form 4s reduce timely transparency and can draw regulatory scrutiny.